Jonathan E. Rosenberg

51.0k total citations · 10 hit papers
404 papers, 13.5k citations indexed

About

Jonathan E. Rosenberg is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jonathan E. Rosenberg has authored 404 papers receiving a total of 13.5k indexed citations (citations by other indexed papers that have themselves been cited), including 313 papers in Surgery, 174 papers in Oncology and 118 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jonathan E. Rosenberg's work include Bladder and Urothelial Cancer Treatments (311 papers), Urinary and Genital Oncology Studies (168 papers) and Cancer Immunotherapy and Biomarkers (116 papers). Jonathan E. Rosenberg is often cited by papers focused on Bladder and Urothelial Cancer Treatments (311 papers), Urinary and Genital Oncology Studies (168 papers) and Cancer Immunotherapy and Biomarkers (116 papers). Jonathan E. Rosenberg collaborates with scholars based in United States, Italy and France. Jonathan E. Rosenberg's co-authors include Joaquim Bellmunt, Daniel P. Petrylak, Eric J. Small, Toni K. Choueiri, Dean F. Bajorin, Guru Sonpavde, Elisabeth I. Heath, Brian I. Rini, Bernard H. Bochner and Matthew D. Galsky and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Genetics.

In The Last Decade

Jonathan E. Rosenberg

393 papers receiving 13.3k citations

Hit Papers

Bevacizumab Plus Interferon Alfa Compared With Interferon... 2008 2026 2014 2020 2008 2021 2017 2016 2019 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
    2008 707 citations Brian I. Rini, Jonathan E. Rosenberg et al. Journal of Clinical Oncology profile →
  2. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
    2021 670 citations Thomas Powles, Jonathan E. Rosenberg et al. profile →
  3. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
    2017 613 citations Bernard H. Bochner, Jonathan E. Rosenberg et al. profile →
  4. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
    2016 511 citations Padmanee Sharma, Margaret K. Callahan et al. profile →
  5. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
    2019 435 citations Jonathan E. Rosenberg, Peter H. O’Donnell et al. Journal of Clinical Oncology profile →
  6. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
    2020 223 citations Jonathan E. Rosenberg, Srikala S. Sridhar et al. Journal of Clinical Oncology profile →
  7. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
    2021 175 citations Peter H. O’Donnell, Elisabeth I. Heath et al. profile →
  8. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
    2022 163 citations Shilpa Gupta, Jonathan E. Rosenberg et al. Journal of Clinical Oncology profile →
  9. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin
    2022 87 citations Mario E. Lacouture, Anisha B. Patel et al. The Oncologist profile →
  10. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
    2023 84 citations Jonathan E. Rosenberg, Thomas Powles et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonathan E. Rosenberg United States 51 7.0k 5.5k 4.2k 4.1k 2.1k 404 13.5k
Elizabeth R. Plimack United States 50 5.8k 0.8× 7.9k 1.4× 3.6k 0.9× 6.3k 1.5× 2.4k 1.1× 317 14.1k
Noah M. Hahn United States 44 5.7k 0.8× 4.4k 0.8× 2.2k 0.5× 4.5k 1.1× 1.6k 0.8× 261 11.4k
Matthew I. Milowsky United States 51 5.4k 0.8× 3.2k 0.6× 2.7k 0.6× 3.5k 0.9× 1.1k 0.5× 274 10.2k
Yohann Loriot France 52 4.4k 0.6× 6.2k 1.1× 2.4k 0.6× 4.5k 1.1× 1.6k 0.8× 457 11.9k
Thomas Powles United Kingdom 49 5.3k 0.8× 5.9k 1.1× 1.9k 0.5× 2.9k 0.7× 1.0k 0.5× 338 10.6k
Christine Théodore France 39 3.9k 0.6× 3.5k 0.6× 2.1k 0.5× 6.0k 1.5× 1.7k 0.8× 164 10.5k
Mitchell C. Benson United States 52 3.1k 0.4× 2.8k 0.5× 3.9k 0.9× 8.6k 2.1× 2.2k 1.0× 268 13.3k
Ronald B. Natale United States 44 3.1k 0.4× 8.4k 1.5× 3.9k 0.9× 7.6k 1.8× 1.5k 0.7× 170 13.8k
Jens Bedke Germany 36 2.8k 0.4× 3.0k 0.5× 2.7k 0.6× 3.9k 1.0× 1.4k 0.7× 313 7.6k
Claus Rödel Germany 52 9.7k 1.4× 11.3k 2.1× 1.8k 0.4× 3.6k 0.9× 831 0.4× 261 16.1k

Countries citing papers authored by Jonathan E. Rosenberg

Since Specialization
Citations

This map shows the geographic impact of Jonathan E. Rosenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan E. Rosenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan E. Rosenberg more than expected).

Fields of papers citing papers by Jonathan E. Rosenberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan E. Rosenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan E. Rosenberg. The network helps show where Jonathan E. Rosenberg may publish in the future.

Co-authorship network of co-authors of Jonathan E. Rosenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan E. Rosenberg. A scholar is included among the top collaborators of Jonathan E. Rosenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan E. Rosenberg. Jonathan E. Rosenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yip, Wesley, et al.. (2025). Urothelial carcinoma: Perioperative considerations from top to bottom. CA A Cancer Journal for Clinicians. 75(6). 528–551. 1 indexed citations
2.
Das, Jeeban Paul, Thomas Powles, Dean F. Bajorin, et al.. (2024). Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 42(16_suppl). 4581–4581. 1 indexed citations
3.
Guercio, Brendan J., Min Yuen Teo, Ashley Marie Regazzi, et al.. (2024). Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB).. Journal of Clinical Oncology. 42(16_suppl). 4571–4571. 1 indexed citations
4.
Shah, Neil J., Adam Watson, Chelsea Nichols, et al.. (2023). Big data in oncology: Challenges and solutions.. Journal of Clinical Oncology. 41(16_suppl). 6513–6513.
5.
Gupta, Shilpa, Karla V. Ballman, Matt D. Galsky, et al.. (2023). MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).. Journal of Clinical Oncology. 41(16_suppl). TPS4609–TPS4609. 1 indexed citations
6.
Akın, Oğuz, Ramesh Paudyal, Amaresha Shridhar Konar, et al.. (2023). Multiparametric MRI in Era of Artificial Intelligence for Bladder Cancer Therapies. Cancers. 15(22). 5468–5468. 8 indexed citations
7.
Lacouture, Mario E., Anisha B. Patel, Jonathan E. Rosenberg, & Peter H. O’Donnell. (2022). Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. The Oncologist. 27(3). e223–e232. 87 indexed citations breakdown →
8.
Teo, Min Yuen, Hikmat Al‐Ahmadie, Kenneth Seier, et al.. (2021). Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. British Journal of Cancer. 124(7). 1214–1221. 21 indexed citations
9.
Wong, Jeffrey L. & Jonathan E. Rosenberg. (2021). Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. Expert Opinion on Biological Therapy. 21(7). 863–873. 39 indexed citations
10.
Heath, Elisabeth I. & Jonathan E. Rosenberg. (2020). The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nature Reviews Urology. 18(2). 93–103. 137 indexed citations
11.
Hong, Andrew L., Jennifer L. Guerriero, Mihir B. Doshi, et al.. (2019). MCL1 and DEDD Promote Urothelial Carcinoma Progression. Molecular Cancer Research. 17(6). 1294–1304. 4 indexed citations
12.
Sharma, Padmanee, Arlene O. Siefker‐Radtke, Filippo de Braud, et al.. (2019). Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. Journal of Clinical Oncology. 37(19). 1608–1616. 178 indexed citations
13.
Teo, Min Yuen, Richard Bambury, Emily C. Zabor, et al.. (2017). DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research. 23(14). 3610–3618. 189 indexed citations
14.
Kim, Jaegil, Kent W. Mouw, Paz Polak, et al.. (2016). Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nature Genetics. 48(6). 600–606. 233 indexed citations
15.
Faltas, Bishoy M., et al.. (2015). Novel molecular targets for urothelial carcinoma. Expert Opinion on Therapeutic Targets. 19(4). 515–525. 8 indexed citations
16.
Choueiri, Toni K., André P. Fay, Robert Gagnon, et al.. (2013). The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma. Clinical Cancer Research. 19(18). 5218–5226. 73 indexed citations
17.
Riester, Markus, Jennifer M. Taylor, Andrew Feifer, et al.. (2012). Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer. Clinical Cancer Research. 18(5). 1323–1333. 177 indexed citations
18.
Rini, Brian I., M. Dror Michaelson, Jonathan E. Rosenberg, et al.. (2008). Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 26(22). 3743–3748. 321 indexed citations
19.
Lin, Amy, Brian I. Rini, Mika K. Derynck, et al.. (2007). A Phase I Trial of Docetaxel/Estramustine/Imatinib in Patients with Hormone-Refractory Prostate Cancer. Clinical Genitourinary Cancer. 5(5). 323–328. 24 indexed citations
20.
Li, Shang, Jonathan E. Rosenberg, Annemarie A. Donjacour, et al.. (2004). Rapid Inhibition of Cancer Cell Growth Induced by Lentiviral Delivery and Expression of Mutant-Template Telomerase RNA and Anti-telomerase Short-Interfering RNA. Cancer Research. 64(14). 4833–4840. 153 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth R. Plimack Breakdown of academic impact, for papers by Noah M. Hahn Breakdown of academic impact, for papers by Matthew I. Milowsky Breakdown of academic impact, for papers by Yohann Loriot Breakdown of academic impact, for papers by Thomas Powles Breakdown of academic impact, for papers by Christine Théodore Breakdown of academic impact, for papers by Mitchell C. Benson Breakdown of academic impact, for papers by Ronald B. Natale Breakdown of academic impact, for papers by Jens Bedke Breakdown of academic impact, for papers by Claus Rödel
Rankless by CCL
2026